What Has Been the Growth of the Difficult-to-Express Proteins Market So Far?
The difficult-to-express proteins market has seen considerable growth due to a variety of factors.
•The market for proteins that are challenging to express has seen a surge in growth in the past few years. The market valuation is projected to increase from $4.65 billion in 2024 to $5.22 billion in 2025, sustaining a compound annual growth rate (CAGR) of 12.1%.
The noteworthiness in the previous periods' growth is credited to the escalated requirement for protein therapeutics, issues in developing drugs, advancements in biopharmaceuticals, restrictions in technology, and progress in gene editing and engineering.
What Are the Future Growth Projections for the Difficult-to-Express Proteins Market?
The difficult-to-express proteins market is expected to maintain its strong growth trajectory in upcoming years.
• The market for proteins which are challenging to express is anticipated to experience swift expansion in the years ahead. The market's value is projected to reach $8.05 billion by 2029, surging at a compound annual growth rate (CAGR) of 11.4%.
This surge over the projection years can be credited to the innovation of novel expression systems, the advent of advanced gene editing tools, improvements in cell-free systems, progress in protein engineering, and the incorporation of AI and machine learning. Expected trends during this period encompass pioneering protein folding technologies, broader utilisation of synthetic biology, precise protein modifications, advancements in biophysical characterization, and a greater implementation of CRISPR/CAS technology.
Which Factors Are Boosting Growth In The Difficult-to-Express Proteins Market?
The difficult-to-express protein market is predicted to expand due to the growing need for recombinant proteins. These kind of proteins are synthesized using recombinant DNA, which is modified DNA created to replicate the genetic structure of a specific protein. Roles of these difficult-to-express proteins, used in the manufacturing of recombinant proteins, include investigating specific activities, protein-protein associations, and creating novel treatments for intricate medical disorders. For example, Amgen Inc., an American biopharmaceutical company, reported in 2022 that Prolia (Denosumab) - a recombinant human monoclonal antibody (protein) had experienced a 12% sales increase from the previous year, making $3,628 million in 2022 compared to $3,248 million in 2021. Hence, the surge in requirement for recombinant proteins contributes to the evolution of the difficult-to-express protein market.
What Key Areas Define The Segmentation Of The Global Difficult-to-Express Proteins Market?
The difficult-to-express proteins market covered in this report is segmented –
1) By Protein: Proteases, Kinases, Membrane Proteins, Other Proteins
2) By Expression Of Difficult Proteins: Disulfide-bonded Protein Expression, Membrane Protein Expression, Toxic Protein Expression, Target Protein Insolubility
3) By Technology: Cell-free Protein Synthesis, Prokaryotic Expression Systems, Small Ubiquitin-like Modifier (SUMO) Fusion System, Gene Fusion Systems, Other Technologies
4) By Application: Drug Discovery, Protein Purification, Protein Therapeutics, Disease Diagnostics And Monitoring, Other Applications
Subsegments:
1) By Proteases: Serine Proteases, Cysteine Proteases, Aspartic Proteases, Metalloproteases
2) By Kinases: Receptor Tyrosine Kinases, Serine Or Threonine Kinases, Cyclin-Dependent Kinases
3) By Membrane Proteins: G-Protein Coupled Receptors (GPCRs), Ion Channels, Transporters
4) By Other Proteins: Transcription Factors, Structural Proteins, Enzymes
Pre-Book The Difficult-to-Express Proteins Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Difficult-to-Express Proteins Market?
In the challenging milieu of the difficult-to-express protein market, one of the primary trends catching on is the creation of pioneering technological solutions. To maintain their market prominence, leading companies are investing in the development of groundbreaking technologies. For instance, Evozyne, an American biotech firm, introduced an innovative AI model named Protein Transformer Variational AutoEncoder in January 2023 to design medicinal proteins. This unique methodology provides a robust framework for accurately training and deploying extensive language models for biology. The outcome is a fresh perspective on deep learning that gives rise to novel opportunities for data-induced design of engineered proteins with customised functionality.
Who Are the Key Players in the Difficult-to-Express Proteins Market?
Major companies operating in the difficult-to-express proteins market include:
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Lonza Group Ltd
• Catalent Inc.
• Sartorius AG
• Charles River Laboratories International Inc.
• Bio-Rad Laboratories Inc.
• Samsung Biologics Co. Ltd.
• Bio-Techne Corp.
• GenScript Biotech Corporation
• Ajinomoto Bio-Pharma Services
• Novasep Holding SAS
• Rentschler Biopharma SE
• BioLegend Inc.
• Codexis Inc.
• Enzo Biochem Inc.
• Sino Biological Inc.
• Horizon Discovery Ltd.
• Creative Biolabs Inc.
• OriGene Technologies Inc.
• Celonic AG
• Cube Biotech GmbH
• Lucigen Corporation
• Batavia Biosciences Inc.
• Cytovance Biologics Inc.
• Alloy Therapeutics Inc.
• Aragen Bioscience Inc.
• Selexis SA
• LifeSensors Inc.
• Bionova Scientific Inc.
What Is The Most Dominant Region In The Difficult-to-Express Proteins Market?
North America was the largest region in the difficult-to-express proteins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the difficult-to-express proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
